Metropolis Healthcare Limited — Important, 04-07-2025: General Updates

Metropolis has announced a board meeting to approve the financial results for the quarter and half-year. Q1FY26 saw consolidated revenue growth of ~23% YoY, driven by recent acquisitions (Core Diagnostics, Scientific Pathology, DAPIC). Core Diagnostics shifted from breakeven to positive margins, while DAPIC and Scientific outperformed company averages. Specialty revenues grew over 35%, led by oncology testing. Organic growth (excluding acquisitions) was 13% YoY, with B2C revenue up 15%. TruHealth Wellness and Specialty segments rose ~20% and ~15% YoY. EBITDA improved QoQ due to higher throughput and efficiencies. The company remains debt free.